| Vol. 14.04 – 31 January, 2023 |
| |
|
|
| Researchers studied 2,391 single-class I HLA-mismatched and 14,426 fully HLA-matched unrelated donor hematopoietic cell transplantation performed between 2008 and 2018 for acute leukemia or myelodysplastic syndromes. [Journal of Clinical Oncology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To further investigate the impact of C1 inhibitor deficiency on activation of coagulation and thrombosis, scientists conducted studies using patient samples and mouse models. [Blood] |
|
|
|
| By investigating alloantibodies to a high-prevalence antigen of unknown specificity, found in patients with a rare blood type, the authors showed that SLC44A2 was also expressed in red blood cells and carried a new blood group system. [EMBO Molecular Medicine] |
|
|
|
| Scientists studied the expression of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD226 in a cohort of 115 chronic lymphocytic leukemia patients and reported the expression of TIGIT and CD226 by leukemic cells. [Haematologica] |
|
|
|
| The authors utilized genetic and compound library screening approaches to identify rational combination treatment strategies to improve the use of vitamin C as adjuvant therapy for AML. [Cell Reports] |
|
|
|
| Investigators showed a significant upregulation of EVA1A protein associated with the increase of endoplasmic reticulum stress during hematopoietic regeneration. [Cell Death & Disease] |
| |
|
|
| To further assess the long-term benefits and risks of asciminib compared with those of bosutinib in patients with chronic myeloid leukemia in the chronic phase after ≥2 prior tyrosine kinase inhibitors, scientists reported efficacy and safety results in ASCEMBL after a median follow-up of 2.3 years. [Leukemia] |
|
|
|
| Researchers investigated ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia, evaluating the tolerability of three sequencing regimens as well as overall safety and efficacy. [Leukemia] |
|
|
|
| Scientists studied the prevalence and risk factors associated with pegylated (PEG)-asparaginase discontinuation in young adults with ALL treated in the US intergroup Cancer and Leukemia Group B (CALGB) 10403 study and examined the prognostic impact of early discontinuation on survival outcomes. [Blood Advances] |
|
|
|
|
| Contrary to the classical path using growth factors to activate tissue regeneration, a novel strategy is emerging to prevent chemotherapy toxicity that involves the temporary cell-cycle arrest of normal cells, such as hematopoietic or epithelial precursors. This proactive approach may allow the sparing of the stem cell reserve of these tissues. [Drugs & Aging] |
|
|
|
|
| The FDA announced draft guidelines that would do away with the current three-month abstinence requirement for donations from men who have sex with men. Potential donors would be screened with a questionnaire that evaluates their risks for HIV based on factors like sexual behavior and recent partners. [Stat News] |
|
|
|
|
| February 9 – 12, 2023 Cancun, Mexico |
|
|
|
|
|
| Swiss Federal Institute of Technology in Lausanne – Lausanne, Switzerland |
|
|
|
| Dresden University of Technology – Dresden, Germany |
|
|
|
| Lund University – Lund, Sweden |
|
|
|
| Hebrew University of Jerusalem – Jerusalem, Israel |
|
|
|
| Upstate Medical University – Syracuse, New York, United States |
|
|
|
|